Zenas BioPharma, Inc.
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $10.0M
- Net income
- -$377.7M
- Total assets
- $383.6M
- Market cap
- $1.1B
- Operating margin
- -3277.8%
- Net margin
- -3139.8%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $5.0M
- Operating expenses
- $168.9M
- Operating income
- -$163.9M
- Income tax
- $429.0K
- Net income
- -$157.0M
- EPS (basic)
- $-11.89
- EPS (diluted)
- $-11.89
Balance sheet
- Total assets
- $370.0M
- Current assets
- $355.9M
- Total liabilities
- $57.5M
- Current liabilities
- $57.3M
- Shareholders’ equity
- $312.5M
Cash flow
- Operating cash flow
- -$119.7M
- Investing cash flow
- -$30.6M
- Financing cash flow
- $413.0M
- Net cash flow
- $262.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.1B
- EPS (diluted)
- $-11.89
- Dividend yield
- 0.04%
- Shares outstanding
- 62.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 13, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $377.7M in FY2025.
- Trading 59% below its 52-week high.
- Pays a dividend yielding about 0.04% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Zenas BioPharma, Inc..
Write a review
News about Zenas BioPharma, Inc.
News & sentiment via Polygon.io
